Key result
Adjunctive Angio-Seal use with dual Perclose ProGlide during transfemoral TAVR showed no significant difference in major vascular complications compared to dual ProGlide alone.
Why the study?
Does adjunctive Angio-Seal use safely augment dual Perclose ProGlide in achieving haemostasis in patients undergoing transfemoral percutaneous TAVR?
Cohort (n=387)
Does adjunctive Angio-Seal use safely augment dual Perclose ProGlide in achieving haemostasis in patients undergoing transfemoral percutaneous TAVR?
The adjunctive use of Angio-Seal to augment a dual Perclose ProGlide strategy for femoral closure after TAVR is safe and feasible as a bail-out strategy.
Answers are grounded in this paper and cite their sources.
Should not change dual ProGlide practice; leaves open the role of adjunctive Angio-Seal pending randomized trials.
AIMS: The objective of this study was to describe and evaluate the adjunctive technique of Angio-Seal (AS) use to augment the dual Perclose ProGlide (PP) in achieving haemostasis in patients undergoing transfemoral percutaneous transcatheter aortic valve replacement (TAVR). METHODS AND RESULTS: All patients who underwent TAVR from May 2007 to January 2015 via a planned transfemoral percutaneous approach with a dual PP pre-close strategy were retrospectively analysed. This cohort was divided into two groups: dual PP versus dual PP with adjunctive AS (PP+AS) use based on the specific status of intraprocedural haemostasis. The baseline and procedural characteristics and in-hospital outcomes were prospectively collected and retrospectively compared. Overall, a total of 387 consecutive patients (55% male, mean age 83 years) with dual PP (n=179) vs. dual PP+AS (n=208) were evaluated. There were no statistically significant differences between the dual PP vs. dual PP+AS groups with regard to the in-hospital Valve Academic Research Consortium-2 (VARC-2) primary endpoints of major vascular complications (8.0% vs. 6.6%, p=0.592), minor vascular complications (18.4% vs. 13.7%, p=0.218), life-threatening or disabling bleeding (5.1% vs. 3.0%, p=0.291), major bleeding (1.7% vs. 1.5%, p=1.000), and minor bleeding (14.4% vs. 10.6%, p=0.271). CONCLUSIONS: The adjunctive Angio-Seal technique to augment the dual PP pre-close strategy for patients undergoing percutaneous femoral closure following TAVR is feasible and safe and may be considered as a bail-out or an alternative strategy when the dual PP closure technique fails to obtain complete haemostasis.
No takes yet. Share an insight, caveat, or question.
Kiramijyan et al. (2016) conducted a cohort in Transfemoral percutaneous transcatheter aortic valve replacement (TAVR) (n=387). Dual Perclose ProGlide with adjunctive Angio-Seal (PP+AS) vs. Dual Perclose ProGlide (PP) alone was evaluated on In-hospital major vascular complications (VARC-2) (p=0.592). Adjunctive Angio-Seal use with dual Perclose ProGlide during transfemoral TAVR showed no significant difference in major vascular complications compared to dual ProGlide alone.
Synapse has enriched 10 related papers. Consider them for comparative context: